14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AXNX vs BSX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Boston Scientific Corp. (BSX) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas BSX carries 60.6/100 (BUY) at $41.98 (13.4x Forward P/E, 19.6% operating margin).
Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs BSX. Trailing 12-month operating profitability (AXNX N/A vs BSX 19.6%) and valuation multiples (AXNX N/M vs BSX 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
BSX Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $62.3B market capitalization and 19.6% operating margin.
OpEx & R&D Reinvestment48.4% of Rev ($10.2B)
90D Engineering Disclosures0 Published
Investor FAQ AXNX vs BSX Key Questions & Quantitative Answers
As of Nov 20, 2026, Boston Scientific Corp. (BSX) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas BSX carries 60.6/100 (BUY) at $41.98 (13.4x Forward P/E, 19.6% operating margin). Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BSX leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BSX at +1.4% YoY revenue growth and -21.5% YoY earnings growth on $21.1B TTM revenue (68.0% gross margin, 19.6% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $21.1B for BSX. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 48.4% of Rev ($10.2B) (0 disclosures) for BSX.
BSX screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BSX trades at 13.4x Forward P/E, 18.1x Trailing P/E, 0.73x PEG, and 3.5x EV/Revenue (6.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus BSX (14.1% ROE) capital efficiency.
In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, BSX carries 74.4% implied volatility (51st %ile, Balanced (25th–60th %ile)), a 1.42x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.34β · 43% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.